Cubist Systematic Strategies LLC Boosts Stock Position in LifeMD, Inc. (NASDAQ:LFMD)

Cubist Systematic Strategies LLC boosted its holdings in shares of LifeMD, Inc. (NASDAQ:LFMD) by 15.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 551,344 shares of the company’s stock after purchasing an additional 72,203 shares during the period. Cubist Systematic Strategies LLC owned about 1.32% of LifeMD worth $3,782,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of LFMD. Quest Partners LLC bought a new stake in shares of LifeMD in the 2nd quarter worth approximately $31,000. Los Angeles Capital Management LLC bought a new stake in LifeMD in the second quarter valued at $88,000. EntryPoint Capital LLC purchased a new position in LifeMD during the 1st quarter valued at $89,000. XTX Topco Ltd bought a new position in LifeMD in the 2nd quarter worth $94,000. Finally, Virtu Financial LLC purchased a new stake in shares of LifeMD in the 1st quarter worth about $249,000. Institutional investors own 35.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on LFMD shares. B. Riley began coverage on shares of LifeMD in a research report on Friday, August 23rd. They set a “buy” rating and a $11.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $15.00 target price on shares of LifeMD in a report on Friday, September 20th. Finally, KeyCorp lowered their target price on LifeMD from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $12.00.

LifeMD Trading Up 0.2 %

NASDAQ:LFMD opened at $5.21 on Friday. The firm has a market capitalization of $224.39 million, a P/E ratio of -7.04 and a beta of 1.19. The company has a debt-to-equity ratio of 10.83, a current ratio of 0.87 and a quick ratio of 0.83. LifeMD, Inc. has a one year low of $4.65 and a one year high of $12.88. The company’s 50-day simple moving average is $5.55 and its 200 day simple moving average is $7.72.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The company had revenue of $50.66 million during the quarter, compared to the consensus estimate of $48.47 million. During the same quarter in the prior year, the firm earned ($0.23) EPS. As a group, analysts forecast that LifeMD, Inc. will post -0.49 EPS for the current fiscal year.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.